Honest Company press release ( HNST ): Q4 GAAP EPS of -$0.21 misses by $0.23 . Revenue of $88.04M (-11.8% Y/Y) misses by $0.53M . Revenue $306 million to $312 million range (or -18% to -16% compared to prior year) Organic Revenue Growth (1) 4% to 6% Adjusted Gross Margin Low 40%s Adjusted EBITDA (2) $20 million to $23 million range Click to enlarge More on Honest Company The Honest Company: Reorganization Brings Efficiency, Not Growth Honest Company Q4 2025 Earnings Preview Central Garden and Honest Company fall after JPMorgan warns on the earnings setup Seeking Alpha’s Quant Rating on Honest Company Historical earnings data for Honest Company

Earnings Call Insights: LivaNova PLC (LIVN) Q4 2025 Management View CEO Vladimir Makatsaria highlighted that "2025 was a year of strong performance for LivaNova. We delivered double-digit revenue growth, meaningful adjusted operating margin expansion and robust cash generation, reflecting strong execution across our cardiopulmonary and epilepsy businesses." He emphasized the company's fifth consecutive year of double-digit EPS growth and the third year of double-digit organic revenue growth. CEO Makatsaria cited strategic progress, particularly the company’s entry into the obstructive sleep apnea (OSA) market, stating, "The first stage of that next chapter is obstructive sleep apnea, where we have a clear right to win based on rigorous clinical evidence, a differentiated technology designed to treat a broader range of challenging patients and our existing neuromodulation capabilities." CEO Makatsaria also announced a key leadership addition: "We recently appointed Lucile Blaise as Global Head of Commercialization for obstructive sleep apnea, further strengthening our leadership team as we prepare to scale the opportunity." CFO Alex Shvartsburg stated, "Revenue in the quarter was $361 million, an increase of 9.5% on a constant currency and organic basis versus the prior year." He added, "Adjusted diluted earnings per share was $0.86 compared to $0.81 in the fourth quarter of 2024." CFO Shvartsburg explained, "Q4 2025 included approximately $0.04 of favorable impact versus prior guidance assumptions related to cardiopulmonary investments, primarily due to timing of the Essenz printed circuit board conversion, where the related costs have been rephased over the rollout period." Outlook CEO Makatsaria guided for "full year 2026 revenue growth between 6% and 7%, which is consistent with the 2025 to 2028 framework detailed at our Investor Day." For cardiopulmonary, "we expect cardiopulmonary revenue to grow 7% to 8%." For epilepsy, "we expect epilepsy revenue growth of 5....

Microsoft (NASDAQ:MSFT) Shares Up 3% - Here's Why MarketBeat

Meta Platforms (NASDAQ:META) Stock Price Up 2.3% - What's Next? MarketBeat

(RTTNews) - Veeco Instruments (VECO) reported earnings for fourth quarter that Drops, from the same period last year

Crescent Energy Company press release ( CRGY ): Q4 GAAP EPS of -$0.03 misses by $0.20 . Revenue of $865.04M (-1.2% Y/Y) misses by $18.31M . More on Crescent Energy Company Crescent Energy: Vital Energy Acquisition Closes Crescent Energy: A Successful Example Of Divestitures And New Acquisitions Crescent Energy Company Q4 2025 Earnings Preview Crescent Energy sells non-operated DJ Basin assets in $90M deal Seeking Alpha’s Quant Rating on Crescent Energy Company

专题：英伟达财报考验在即，成市场关键“定盘星” 英伟达首席执行官黄仁勋 英伟达周三公布 第四财季业绩超预期 ，核心数据中心业务营收同比增长 75% 成为主要 驱动力 。该股在盘后交易上涨。 以下为公司业绩与分析师预期对比： 调整后每股收益：1.62 美元，预期 1.53 美元； 总营收：681.3 亿美元，预期 662.1 亿美元。 英伟达当季总营收同比增长 73%，从去年同期的 393 亿美元增至 681.3 亿美元。目前公司 超过 91% 的收入来自数据中心部门 ，该部门主营市场领先的 AI 芯片。 据 StreetAccount 数据，数据中心季度营收为 623 亿美元 ，高于预期的 606.9 亿美元。 公司在新闻稿中表示，净利润几乎翻倍，从去年同期的 221 亿美元（每股 0.89 美元）增至 430 亿美元（每股 1.76 美元） 。 业绩指引同样好于预期 。英伟达预计第一财季营收为 780 亿美元，上下浮动 2%。分析师预期为 726 亿美元。英伟达表示，其预测 未计入来自中国的数据中心收入 。 今年以来，英伟达股价表现远超其他大型科技股，持续成为 AI 热潮的最大受益者。截至周三收盘，该股 2026 年已上涨 5%，而纳斯达克指数下跌 0.4%。万亿美元市值俱乐部中，今年另一家实现上涨的只有苹果，涨幅不足 1%。 数周前，四大超大规模云服务商 —— Alphabet、亚马逊、Meta、微软公布季度财报后，华尔街已对英伟达业绩有了明确预判。根据它们的资本支出计划及分析师估算，随着科技巨头扩建 AI 基础设施，全年合计资本支出有望接近 7000 亿美元 。 在首席财务官的评论中，英伟达表示，超大规模云服务商 “仍是我们最大的客户类别”，占数据中心收入的 略超 50% 。 数据中心业务中，英伟达网络部件销售额达 109.8 亿美元 ，用于连接数百个GPU，同比大增 263% 。这反映出公司 NVLink 网络技术以及 Spectrum‑X 以太网交换机获得广泛采用，包括来自 Meta 等巨头的新订单。 曾是英伟达最大业务的游戏部门，当季营收同比增长 47%，至 37 亿美元，但环比下降 13%。 分析师推测，由于存储芯片短缺迫使芯片厂商优先生产 AI 处理器，英伟达今年可能 跳过新一代游戏 GPU 发布 。对英伟达而言，这意味着 AI 加速卡主要以机架式系...

A record quarter met a market priced for perfection, and Nvidia answered with revenue and a forecast that reset the AI math — again

Pursuit Attractions and Hospitality press release ( PRSU ): Q4 Non-GAAP EPS of -$0.89 misses by $0.09 . Revenue of $57.07M (-84.4% Y/Y) misses by $1.21M . Shares -3.94% AH. More on Pursuit Attractions and Hospitality Pursuit Attractions & Hospitality makes a strategic licensing move with its Flyover business Seeking Alpha’s Quant Rating on Pursuit Attractions and Hospitality Historical earnings data for Pursuit Attractions and Hospitality Financial information for Pursuit Attractions and Hospitality

The beaten-down database titan has more potential than some realize, according to a new analysis.

Key PointsA pundit changed his recommendation for the better.

Procept press release ( PRCT ): Q4 GAAP EPS of -$0.53 misses by $0.20 . Revenue of $76.4M (+12.0% Y/Y) misses by $17.3M . Full Year 2026 Financial Guidance The Company expects revenue for the full year 2026 to be in the range of $390 million to $410 million, which represents growth of 27% to 33% compared to the prior year period The Company expects full year 2026 U.S. procedure growth to be in the range of 39% to 48% compared to the prior year period The Company expects full year 2026 gross margin to be approximately 65% The Company expects full year 2026 operating expenses to be approximately $350 million The Company expects full year 2026 adjusted EBITDA* loss to be in the range of $30 million to $17 million First Quarter 2026 Financial Guidance The Company expects total procedures for the first quarter of 2026 to be in the range of 12,000 to 12,800, which represents growth of 31% to 36% compared to the prior year period. Total revenue for the first quarter of 2026 is expected to be in the range of $79 million to $82 million dollars, which represents growth of 14% to 19% to the prior year period. More on Procept PROCEPT BioRobotics Corporation (PRCT) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript Seeking Alpha’s Quant Rating on Procept Historical earnings data for Procept Financial information for Procept

Nvidia earnings live: Nvidia stock pops as earnings beat, guidance stifles some AI concerns Yahoo Finance

Samsung’s Galaxy S26 phones introduce a slate of new AI-powered features, including some new photography tools. | Image: Samsung Samsung has just announced its new Galaxy S26 lineup , which includes the S26, S26 Plus, and S26 Ultra. While they aren't radical departures from last year's models, they bring a handful of notable upgrades. All three run on Qualcomm's Galaxy-centric Snapdragon 8 Elite Gen 5, which delivers improved performance and powers a slew of new AI-based features. This includes the ability to screen unknown calls and edit photos by typing what you want changed, along with an update to Google Gemini that can carry out certain tasks in supported third-party apps, like Uber and DoorDash, on your behalf. Starting at $899.99, the S26 is the smallest and mo … Read the full story at The Verge.

Key PointsMedical Properties Trust just raised its dividend by 12.5%.

AMD Surges 9% as Meta Inks Massive Multi-Billion Dollar AI Partnership to Break Chip Monopoly FinancialContent

Check out the companies making headlines in after-hours trading. Nvidia — Nvidia reported strong earnings and revenue for the fiscal fourth-quarter , leading shares to add more than 1% in extended trading. Nvidia reported adjusted earnings of $1.62 per share, while analysts expected $1.53 per share, according to LSEG. The chipmaker's revenue of $68.13 billion for the period also exceeded the $66.21 billion estimated, driven by significant growth in its core data center business. Snowflake – Shares of the software company slipped more than 2%. Snowflake said that its first-quarter product revenue would range between $1.262 billion and $1.267 billion, just slightly higher than the FactSet consensus call for $1.26 billion. Trade Desk — Shares of the advertising tech company plunged about 16% after Trade Desk called for first-quarter adjusted EBITDA, or earnings before interest, taxes, depreciation, and amortization, of roughly $195 million, falling significantly short of the $223 million expected from analysts polled by FactSet. Trade Desk also missed on first-quarter revenue projections, but its fourth-quarter results beat the Street's estimates. Synopsys — The electronic design automation company fell nearly 2% after full-year revenue guidance failed to impress Wall Street. Synopsys sees revenue ranging between $9.56 billion and $9.66 billion, while the LSEG consensus estimates called for $9.63 billion. Salesforce — Shares of the customer service software maker fell about 5% in the after-hours session. Salesforce provided fiscal 2027 revenue guidance ranging from $45.8 billion to $46.2 billion, while the FactSet consensus called for $46.11 billion. Fourth-quarter results surpassed expectations on the top and bottom lines , however. Nutanix — The cloud software company saw its shares pop 17%. Nutanix and AMD announced a multi-year partnership to jointly develop an artificial intelligence infrastructure platform. As part of this agreement, AMD will make a strategic inv...

Recursion Pharmaceuticals (NASDAQ:RXRX) used its latest earnings call to emphasize what management described as an inflection point for the company, highlighting a first positive clinical proof-of-concept in familial adenomatous polyposis (FAP), continued progress in partnerships—most notably a fift

Gold stocks continue to look increasingly lustrous in many investors' eyes.

MONTRÉAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSX-V: PHA ) (the “ Company ”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial Statements and MD&A for its first quarter ended December 31, 2025.

Key PointsNewmont is a leading gold miner with a market capitalization of $135 billion.

filo Agilent ( A ) is down ~3% in after-hours trading as its fiscal 2026 Q1 results missed on both lines. However, it raised its EPS guidance for the year. FY26 non-GAAP EPS is now seen at $5.90-6.04, up from $5.86-$6.00. Consensus is $5.93. Agilent also raised the upper range of its revenue outlook to $7.3B-$7.5B from $7.3B-$7.4B before. Consensus is $7.36B. Q1 non-GAAP EPS of $1.36 compares to $1.31 in the year-ago period. Agilent was hurt in the quarter by year-over-year operating margin percentage declines in two of its three segments: l ife sciences and diagnostics markets and Agilent CrossLab. The company ended the quarter (Jan. 31) with cash and cash equivalents of ~$1.76B compared to ~$1.79B on Oct. 31, 2025. More on Agilent Technologies Agilent Technologies, Inc. (A) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Agilent Technologies, Inc. (A) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Agilent Technologies, Inc. (A) Presents at Citi Annual Global Healthcare Conference 2025 Transcript Agilent Technologies Non-GAAP EPS of $1.36 misses by $0.01, revenue of $1.8B misses by $10M Agilent Technologies Q1 2026 Earnings Preview

Nvidia stock has been trending sideways for the last four months, weighed down by a host of concerns related to the AI megatrend.

Khanchit Khirisutchalual/iStock via Getty Images The last time I spoke about Equillium ( EQ ) it was with respect to a Seeking Alpha article entitled " Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC ". With respect to this article, I went over the fact that the company was in the process of advancing its potent, selective oral AhR modulator EQ504 for the treatment of patients with Ulcerative Colitis [UC]. The company still intends to initiate a phase 1 single-ascending dose/multiple-ascending dose [SAD/MAD] study using EQ504 to treat these UC patients in mid-2026. Upon trial initiation, the company believes that it is going to be able to release initial data from this SAD/MAD early-stage trial six months later. However, this time around, I want to also mention another candidate from its pipeline that it is working on, which is its IL-15/IL-21 inhibitor EQ302. This is being developed as an oral peptide drug to treat patients with celiac disease [CD]. It is still in the early stages of clinical testing [discovery process], but the reason I believe it is important to go over this candidate is because the company intends to partner out this candidate for development. What I will also be going over below is the versatility of this company's ability to use its Multi-Cytokine Platform to be selective in the cytokines that it is going after. Instead of a class of drugs that does broad inhibition and then is plagued with safety issues. For instance, JAK inhibitors work well, but in the family of cytokines, all are targeted. The company's uniqueness is to only go after the cytokines that drive pathogenic disease and then leave the others alone. I placed a "Hold" rating the last time around, and based on the fact that the company is still gearing up to initiate its phase 1 SAD/MAD study using EQ504 for the treatment of patients with UC, plus the ability to partner EQ302 for the targeting of CD, I believe it is worth maintaining a "Hold" rating on th...

(RTTNews) - Zoom Communications, Inc. (ZM) announced earnings for its fourth quarter that Increases, from last year

Alkami Technology press release ( ALKT ): Q4 GAAP EPS of -$0.11 beats by $0.01 . Revenue of $120.8M (+34.7% Y/Y) beats by $0.66M .

Image source: The Motley Fool. Wednesday, Feb. 25, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

格隆汇2月26日｜今日通宝光电(920168.BJ)上市，觅睿科技(920036.BJ)申购。

Source: Bloomberg, 9:50